Study the Effect of Danggui Buxue Tang on Menopausal Symptoms
Launched by CHINESE UNIVERSITY OF HONG KONG · Jan 11, 2007
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Follicle stimulating hormone (FSH), luteinizing hormone (LH), oestradiol in the menopausal range (FSH\>18 IU/L, LH\>12.6 IU/L, and E2\< 361 pmol/l).
- • Patients with amenorrhoea for more than 12 months
- Exclusion Criteria:
- • Patients with a history of using any form of hormonal replacement therapy within 8 weeks
- • Patients with a history of using Chinese medicine or other therapies which may affect the outcome within 8 weeks
- • Patients who in the judgment of the investigator will be unable to comply with protocol requirements
- • Patients with significant\*\* gastrointestinal, renal, hepatic, bronchopulmonary, neurological, cardiovascular, breast or endometrial carcinoma, or allergic diseases
- • Patients with uncontrolled hypertension
- • Patients with undiagnosed vaginal bleeding
- • Patients with a history of significant drug hypersensitivity
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , China
Patients applied
Trial Officials
Christopher J Haines, FPOGS
Principal Investigator
Department of Obstetrics & Gynaecology, CUHK
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials